register

News & Trends - MedTech & Diagnostics

TGA consultation on personalised medical devices manufacturing to ensure fit-for-purpose regulations

Health Industry Hub | April 6, 2023 |

MedTech News: The Therapeutic Goods Administration (TGA) is gathering feedback on the regulatory needs of manufacturing sites for medical devices at the point of care. The consultation is part of TGA’s efforts to understand how the framework for custom-made and personalised medical devices applies to point-of-care device production.

Over the past two decades, rapid advances in computing technology and materials have resulted in significant changes to medical imaging, manufacturing and, as a result, medical device technology. Easier access to this technology and newer methods of manufacture such as 3D-printing allow more complex and, in some cases, higher-risk medical devices to be “personalised” for an individual patient or client.

In 2021, the government introduced a framework intended to apply an appropriate level of regulation to personalised, custom-made devices. The regulatory framework changed the definition of custom-made medical device and, in doing so, required the manufacturers of most products that were previously supplied under an exemption to add their devices to the Australian Register of Therapeutic Goods (ARTG). Products supplied in volumes of more than five a year need to be on the ARTG.

Now, the TGA is working to understand how the framework applies to manufacturing at the point-of-care and “what refinements could be made to ensure regulation is appropriate without introducing unnecessary burden for point-of-care facilities.” The initiative led TGA to post a survey aimed at manufacturing hubs operated by a point-of-care facility, manufacturers based in a point-of-care facility and academic sites.

One question asks respondents what would help them and their facility meet their regulatory obligations for medical devices. The agency also asked manufacturers where they expect to be able to find information about their regulatory obligations, such as from the administration who runs their facility and TGA, and posed multiple questions about the respondents’ organisations.
 
TGA released the consultation alongside three related surveys aimed at allied healthcare professionals, dental and oral health professionals and hospital and healthcare facilities. Each survey is intended to provide TGA with information about how to refine the custom-made medical device regulations to avoid unnecessary burdens. The surveys are tailored to the different sets of stakeholders involved in the point-of-care production of medical devices.

TGA is accepting responses to the survey of medical device manufacturing hubs at the point-of-care and survey of hospital and healthcare facility point-of-care manufacturing by 7 May. The regulator has clarified that the information provided will only be used to inform refinements to the regulatory framework and will not be used for compliance activities.

In reimagining healthcare, Health Industry HubTM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.

The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.


ESG

Surgeons lead push for $1.5 million hospital sustainability project

Surgeons lead push for $1.5 million hospital sustainability project

Health Industry Hub | October 23, 2024 |

ESG: Australia’s healthcare sector contributes 7% of the country’s total emissions. The Royal Australasian College of Surgeons (RACS) has joined […]

More


News & Trends - MedTech & Diagnostics

AI-assisted colonoscopy boosts polyp and adenoma detection

AI-assisted colonoscopy boosts polyp and adenoma detection

Health Industry Hub | October 23, 2024 |

MedTech & Diagnostics News: In a standard colonoscopy, as many as one-third of colorectal polyps and adenomas can go by […]

More


News & Trends - Pharmaceuticals

'Every day of delay is costing Australian lives', says Rare Cancers Australia CEO

‘Every day of delay is costing Australian lives’, says Rare Cancers Australia CEO

Health Industry Hub | October 23, 2024 |

Pharma News: Rare Cancers Australia (RCA) has voiced its disappointment alongside the pharmaceutical industry following the Pharmaceutical Benefits Advisory Committee’s […]

More


News & Trends - Pharmaceuticals

Government's silence on Senate report leaves cancer patients in limbo

Government’s silence on Senate report leaves cancer patients in limbo

Health Industry Hub | October 23, 2024 |

Pharma News: NeuroEndocrine Cancer Australia has urged the government to respond to the Senate report on equitable access to diagnosis […]

More


This content is copyright protected. Please subscribe to gain access.